Journal
PET CLINICS
Volume 3, Issue 1, Pages 89-+Publisher
ELSEVIER INC
DOI: 10.1016/j.cpet.2008.09.003
Keywords
PET; Therapeutic monitoring; FDG; SUV; Cancer
Ask authors/readers for more resources
After diagnosis and staging of cancer, the most important process in modern oncology is assessment of therapeutic response. Timely identification of patients with poor response may allow introduction of alternative therapies, sparing patients the toxicity of ineffective treatments, reducing health care cost, and potentially delivering better outcomes. Metabolic imaging using PET is increasingly recognized as providing earlier and more robust assessment than conventional imaging. There are now ample clinical data indicating that PET metabolic response should be strongly considered for inclusion in evaluation of clinical response in individual high-risk malignancies to both direct the care of individual patients and to guide application of new therapies in particular cancer populations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available